Polyposis Syndromes (FAP, Lynch, Peutz-Jeghers, Juvenile)

USMLE Step 1 trap: Dismisses cancer risk in Peutz-Jeghers syndrome because hamartomas are not adenomas. Peutz-Jeghers syndrome carries significantly increased risk of GI and non-GI cancers (breast, pancreas, ovary, cervix) despite the polyps themselves being hamartomas with low direct malignant potential.

Polyposis syndromes are a group of inherited conditions that dramatically elevate colorectal cancer (CRC) risk through distinct genetic and pathologic mechanisms. USMLE Step 1 tests this topic more broadly than just memorizing gene names — you need to know each syndrome's polyp type, extra-GI features, and how the diagnosis is actually made in clinical practice. The four you must know cold: FAP (APC mutation, thousands of adenomas), Lynch/HNPCC (MMR gene mutations, no polyposis), Peutz-Jeghers (STK11, hamartomas + mucocutaneous pigmentation), and Juvenile Polyposis (SMAD4/BMPR1A, hamartomatous polyps in kids).

The exam loves to test these syndromes through clinical vignettes where a key detail — a skin finding, a family history pattern, a tumor test result — points to one syndrome over another. It also tests pathology interpretation: knowing whether a polyp is a hamartoma or adenoma changes the clinical implications. The tricky part is that 'hamartoma' sounds benign, which leads students to dismiss cancer risk in Peutz-Jeghers — a classic wrong answer trap. Similarly, many students conflate Lynch syndrome with FAP because both involve hereditary CRC risk, missing the critical point that Lynch has no polyposis phenotype.

On USMLE Step 1, FAP questions often include Gardner syndrome variants (desmoid tumors, osteomas, CHRPE) that students overlook. Lynch syndrome questions frequently hinge on tumor testing — MSI or MMR immunohistochemistry — not just family history. Nail the mechanistic differences and the diagnostic workup for each, and this topic becomes a reliable point-getter.

From real student decks

65%have cards covering this topic

35%have mature cards

Common misconceptions

Common mistake

Wrong: Peutz-Jeghers hamartomas have no malignant potential because hamartomas are benign.

Right: Peutz-Jeghers syndrome carries significantly increased risk of GI and non-GI cancers (breast, pancreas, ovary, cervix) despite the polyps themselves being hamartomas with low direct malignant potential.

Hamartomas are disorganized but architecturally normal tissue — they lack the dysplastic features of adenomas, so the polyps themselves rarely become malignant. However, Peutz-Jeghers syndrome is not a low-cancer-risk condition: patients have substantially elevated risk of GI cancers (small bowel, colon, stomach) and non-GI cancers including breast, pancreatic, ovarian, and cervical malignancies. The cancer risk is tied to the STK11 tumor suppressor mutation, not to malignant transformation of the hamartomas themselves — so the polyp histology and the syndrome's cancer risk are two separate issues.

Common mistake

Wrong: Lynch syndrome is characterized by hundreds of colonic polyps similar to FAP.

Right: Lynch syndrome (HNPCC) causes markedly elevated CRC risk without polyposis; FAP is defined by hundreds to thousands of adenomatous polyps due to APC mutation.

FAP is literally defined by polyposis — hundreds to thousands of adenomatous polyps carpeting the colon due to APC loss-of-function. Lynch syndrome (HNPCC) has nothing to do with polyposis; it causes high CRC risk through defective DNA mismatch repair, leading to microsatellite instability in tumors that arise from normal-looking mucosa. If you see a vignette describing a patient with countless polyps, think FAP. If the vignette emphasizes a strong family history of CRC (and often endometrial cancer) without polyposis, think Lynch.

Common mistake

Gap: Misses the extracolonic features of FAP, particularly desmoid tumors and osteomas in Gardner syndrome

FAP is associated with extracolonic manifestations including desmoid tumors, osteomas, congenital hypertrophy of the retinal pigment epithelium (CHRPE), and epidermoid cysts (Gardner syndrome variant).

FAP from APC mutation causes near-certain colon cancer if untreated, but APC loss drives extracolonic pathology too. Gardner syndrome is the variant where patients additionally develop desmoid tumors (locally aggressive fibromatoses, especially post-surgical), osteomas of the skull and jaw, congenital hypertrophy of the retinal pigment epithelium (CHRPE — a fundoscopic finding), and epidermoid cysts. These extracolonic findings can actually appear before colonic polyposis, so a vignette mentioning jaw osteomas or CHRPE in a young patient should immediately make you think FAP/Gardner.

Common mistake

Wrong: Lynch syndrome is diagnosed solely by family history criteria without tumor testing.

Right: Lynch syndrome diagnosis involves tumor testing for microsatellite instability (MSI) or immunohistochemistry for mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), followed by germline genetic testing.

Family history criteria (like Amsterdam criteria) can suggest Lynch syndrome, but clinical diagnosis requires tumor-level evidence of MMR deficiency. The standard workup tests the tumor — either by PCR for microsatellite instability (MSI-high = MMR deficient) or by immunohistochemistry looking for absent expression of MLH1, MSH2, MSH6, or PMS2 protein. Loss of any of these proteins on IHC points to a specific gene defect. Only after tumor testing is confirmatory germline genetic testing performed. Skipping tumor testing and relying on family history alone misses sporadic MSI-high tumors and leads to incorrect classification.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Given a syndrome, identify the responsible gene, the type of polyp produced (adenoma vs. hamartoma vs. juvenile), and any distinctive extracolonic features — for example, matching STK11 mutation with Peutz-Jeghers and its mucocutaneous pigmentation, or APC mutation with FAP and its Gardner variant findings.
Distinguish hamartomas from adenomas on histology and understand why polyp type matters for malignant potential — specifically, why hamartomas in Peutz-Jeghers carry real cancer risk even though the polyps themselves rarely undergo malignant transformation.
Know the full diagnostic workup for Lynch syndrome: recognize when family history alone is insufficient, understand when to order microsatellite instability (MSI) testing or MMR protein immunohistochemistry, and know which four proteins (MLH1, MSH2, MSH6, PMS2) are tested and what a loss-of-expression result means.

Can you avoid these mistakes?

A 16-year-old is found to have jaw osteomas and multiple pigmented retinal lesions on routine eye exam. Colonoscopy reveals hundreds of adenomatous polyps. What gene is mutated, what syndrome variant is this, and what is the lifetime CRC risk without intervention?

A tumor is removed from a 45-year-old with a strong family history of colon and endometrial cancer. Immunohistochemistry of the tumor shows absent MSH2 staining with normal MLH1, MSH6, and PMS2. What does this result indicate, and what should be done next?

A patient with Peutz-Jeghers syndrome asks if her hamartomatous polyps are dangerous. Her gastroenterologist says the polyps themselves are not adenomas and rarely become malignant. Does this mean she has normal cancer risk? What cancers is she actually at elevated risk for?

Distinguish Lynch syndrome from FAP in one sentence each: what is the polyp burden, the causative gene/pathway, and one distinctive extracolonic feature (or lack thereof) for each syndrome?

Polyposis Syndromes (FAP, Lynch, Peutz-Jeghers, Juvenile)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics